Nektar Therapeutics

NKTR55

Penny Stock

$1.13arrow_drop_up6.54%$0.06

Penny Stock

NKTR55

$1.13

arrow_drop_up6.54%$0.06

Penny Stock

Performance History

Key Stats
Open	$1.11
Prev. Close	$1.07
EPS	-0.84
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$208.43M
PE Ratio	-

	LOW	HIGH
Day Range	1.08	1.20
52 Week Range	0.41	1.93

Ratios







EPS	-0.84

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) is a biopharmaceutical company focused on developing innovative medicines to address the unmet needs of patients. With a strong pipeline of potential therapies across various therapeutic areas, Nektar Therapeutics is committed to improving the lives of patients worldwide. The company's stock price history reflects its growth and potential. Over the years, NKTR stock has shown steady growth, with occasional dips and recoveries. Its value has been influenced by market dynamics, clinical trial results, and advancements in the biotechnology sector.

As of the latest quote, Nektar Therapeutics (NKTR) continues to show promise in the market. The company's dedication to advancing science and delivering impactful therapies has garnered positive attention from investors. NKTR stock has been performing well, and the latest news surrounding the company reinforces its position as a leader in the biopharmaceutical industry. With its strong pipeline and strategic partnerships, Nektar Therapeutics is poised for continued success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Howard W. Robin
Headquarters: San Francisco
Employees: 216
Exchange: NASDAQ

Keep an eye on Nektar Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Nektar Therapeutics's (NKTR) price per share?

The current price per share for Nektar Therapeutics (NKTR) is $1.13. The stock has seen a price change of $0.07 recently, indicating a 6.54% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Nektar Therapeutics (NKTR)?

For Nektar Therapeutics (NKTR), the 52-week high is $1.93, which is 70.8% from the current price. The 52-week low is $0.41, the current price is 175.61% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Nektar Therapeutics (NKTR) a growth stock?

Nektar Therapeutics (NKTR) has shown an average price growth of -3.72% over the past three years. It has received a score of 34 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nektar Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Nektar Therapeutics (NKTR) stock price performance year to date (YTD)?

As of the latest data, Nektar Therapeutics (NKTR) has a year-to-date price change of 89.98%. Over the past month, the stock has experienced a price change of -16.91%. Over the last three months, the change has been -9.6%. Over the past six months, the figure is -24.67%. Looking at a longer horizon, the five-year price change stands at -94.5%.

help

Is Nektar Therapeutics (NKTR) a profitable company?

Nektar Therapeutics (NKTR) has a net income of -$276.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.34% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -142.18% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $90.12M, although specific revenue growth data is currently not available. The gross profit is $53.48M. Operating income is noted at -$137.42M. Furthermore, the EBITDA is -$130.18M.

help

What is the market capitalization of Nektar Therapeutics (NKTR)?

Nektar Therapeutics (NKTR) has a market capitalization of $208.44M. The average daily trading volume is 1.12, indicating the stock's liquidity and investor engagement.